A subscription to JoVE is required to view this content. Sign in or start your free trial.
Presented here is a protocol to measure absolute myocardial flow and resistance using continuous thermodilution in patients with ischemia and nonobstructive coronary artery disease.
In approximately half of the patients undergoing coronary angiography for angina pectoris or for signs or symptoms suggestive of ischemic heart disease, no obstructive coronary artery disease is angiographically visible. The majority of these patients with angina or ischemia and no obstructive coronary artery disease (INOCA) have an underlying coronary vasomotor dysfunction, and current consensus documents recommend diagnostic invasive coronary vasomotor function testing (CFT).
During CFT, a variety of vasomotor dysfunction endotypes can be assessed, including vasospastic coronary dysfunction (epicardial or microvascular vasospasm), and/or microvascular vasodilatory dysfunction, including impaired vasodilatory capacity and increased microvascular resistance. The quantification of the continuous thermodilution derived absolute coronary blood flow and resistance might be a better measure compared to the currently used standard physiologic measures. This article provides an overview of this continuous thermodilution method.
In approximately half of the patients undergoing coronary angiography for angina pectoris or for signs or symptoms suggestive of ischemic heart disease, no obstructive coronary artery disease is angiographically visible1. The majority of these patients with angina or ischemia and no obstructive coronary artery disease (INOCA) have an underlying coronary vasomotor dysfunction, and current ESC guidelines and a recent ESC position paper on INOCA recommend diagnostic invasive coronary vasomotor function testing (CFT)1,2.
During CFT, a variety of vasomotor dysfunction endotypes can be assessed, including vasospastic coronary dysfunction (epicardial or microvascular vasospasm), and/or microvascular vasodilatory dysfunction, including impaired vasodilatory capacity and increased microvascular resistance. Consensus criteria for these endotypes have been defined by the Coronary Vasomotion Disorders International Study Group (COVADIS)3,4.
While vasospastic coronary dysfunction is generally demonstrated by acetylcholine provocation testing, the diagnosis of microvascular vasodilatory dysfunction is more complex. This diagnosis is made by an abnormal index of microvascular resistance (IMR) and/or coronary flow reserve (CFR)4.
Two methods exist for the measurement of IMR or CFR: thermodilution or Doppler flow velocity. Both use intravenous adenosine to induce maximal hyperemia (and thus minimal resistance), and both methods have been extensively validated. However, they do have several important shortcomings: the need for adenosine limits their use in patients with severe chronic obstructive pulmonary disease or asthma. Also, the thermodilution method may overestimate the CFR and has a large intra-observer variability, and with the Doppler flow velocity methods it can be challenging to obtain a stable Doppler flow signal5. Most importantly, both CFR and IMR are only surrogate measures and fail to quantify true coronary blood flow and resistance.
Absolute coronary blood flow (Q) and resistance (R) can be directly quantified with the use of a recently validated and novel method that uses continuous thermodilution with intracoronary saline infusion at room-temperature to induce hyperemia. A dedicated monorail infusion catheter and a pressure wire with temperature sensors enables direct quantification of Q and R, without the use of adenosine. This novel method has been shown to be safe, highly reproducible and operator-independent 6,7.
As has been urged by a recent consensus statement, we need a better understanding of the underlying mechanism of myocardial ischemia in patients with INOCA, across the different endotypes1. This could have major implications for treatment and prognosis. The quantification of the absolute coronary blood flow and resistance might be a better measure compared to the currently used standard physiologic measures. It was recently shown that continuous thermodilution measurements are associated with symptoms in INOCA, while IMR and CFR were not8. Additional outcome data will follow. In this article, the continuous thermodilution protocol is described.
The following protocol was approved by the local medical ethics committee at the Radboudumc hospital, Nijmegen, the Netherlands. The following steps should be followed when performing continuous thermodilution to calculate absolute flow and resistance.
1. Preparations
2. Diagnostic Coronary Angiography
3. Set up of continuous thermodilution measurements
4. Continuous thermodilution measurements
5. Calculation of absolute flow and absolute resistance
NOTE: As shown in Figure 1, the dedicated monorail infusion catheter allows the infusion of saline only through four outer side holes, resulting in complete and optimal mixing with blood; two inner side holes allow the measurement of temperature by the used guidewire.
Figure 2 shows a representative measurement performed in patient A with no obstructive CAD on coronary angiography. The LAD artery was measured using continuous thermodilution to calculate absolute Q and R. The red and green lines represent pressure measurements, and the blue line represents the temperature curve. The infusion rate was set at 20 mL/min (Qi) since the LAD artery was measured. At point 1, the infusion was started and the temperature measured at the distally placed pressur...
Continuous thermodilution is an accurate method to measure absolute coronary flow and resistance, which has been shown to strongly agree with the gold standard [15O2]H2O PET derived flow and resistance5. These measurements are of special interest in INOCA patients, with current clinical guidelines recommending the assessment of coronary flow and resistance in this group.
Fractional flow reserve (FFR), the ratio of the maximal myocardial ...
Peter Damman received lecture and/or consultancy fees from Phillips and Abbott Vascular.
None.
Name | Company | Catalog Number | Comments |
Rayflow multipurpose infusion catheter | Hexacath | RFW61S | Only compatible with 6F guiding catheter |
PressureWire X guidewire | Abbott | C12059 | Wireless guidewire with distal temperature and pressure sensor |
Coroventis CoroFlow Cardiovascular System software | Coroventis | N/A | Advanced platform to measure physiological indices |
Illumena Neo injector or similar injector system | Liebel-Flarsheim | GU01181006-E | Any injector with pressure limit (600 psi) and adjustable flow and volume injection rate |
100 ml NaCl 0.9% at room temperature |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved